Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403200 | 0.86 | MAPT (0.49) | KDM4EMAPTSMN1; SMN2TSHRPOLB | |
| SCHEMBL295426 | 0.84 | MAPT (0.48) | KDM4EMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL8268871 | 0.83 | MAPT (0.47) | KDM4EMAPTSMN1; SMN2TSHRPOLB | |
| SCHEMBL293902 | 0.81 | GSK3A (0.44) | KDM4EMAPTKMT2AMEN1MAPK1 | |
| SCHEMBL293409 | 0.81 | GSK3A (0.44) | KDM4EMAPTKMT2AMEN1MAPK1 | |
| SCHEMBL293972 | 0.81 | GSK3A (0.44) | KDM4EMAPTKMT2AMEN1MAPK1 | |
| SCHEMBL364227 | 0.80 | KDM4E (0.49) | KDM4EMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL293957 | 0.79 | MAPT (0.44) | KDM4EMAPTKMT2AMEN1MAPK1 | |
| SCHEMBL363607 | 0.76 | ADORA3 (0.43) | KDM4EMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7266087 | 0.74 | ACHE (0.48) | KDM4EMAPTKMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888589-B1 | PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-1888589-B1 | PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| US-7521557-B2 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521557-B2 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1888589-A2 | PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | Brystol-Myers Squibb Company (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127287-A2 | PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-23 | — | — | US | disclosed |
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | KDM4E 821/4885MAPT 4195/4885KMT2A 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.